Literature DB >> 20883481

Radical nephrectomy with vena caval thrombectomy: a contemporary experience.

Matthew G Kaag1, Christien Toyen, Paul Russo, Angel Cronin, R Houston Thompson, Jeffrey Schiff, Melanie Bernstein, Manjit Bains.   

Abstract

OBJECTIVE: • To report on the contemporary Memorial Sloan-Kettering Cancer Center experience with radical nephrectomy and vena caval thrombectomy. PATIENTS AND METHODS: • Patients who underwent radical nephrectomy and vena caval thrombectomy without the use of bypass techniques were retrospectively identified. • Data were collected on intraoperative and pathological findings as well as postoperative complications and oncological outcomes.
RESULTS: • In all, 78 patients underwent radical nephrectomy with off-bypass resection of vena caval thrombus between 1989 and 2009. • The median (interquartile range, IQR) operation duration was 293 (226-370) min, and median (IQR) blood loss was 1300 (750-2500) mL. In all, 10 patients (13%) were confirmed to have intra- or supra-hepatic tumour thrombus (level 3/4), eight of whom required supra-hepatic control of the inferior vena cava (IVC). • Major (grade 3-5) postoperative complications occurred in 14 (18%), with five postoperative deaths. Disease recurred in 27/62 patients who were considered completely resected at surgery and had adequate follow-up. • The overall 5-year survival (95% confidence interval) probability was 48% (35-60%).
CONCLUSIONS: • Radical nephrectomy with vena caval thrombectomy is associated with acceptable postoperative morbidity and mortality, and long-term survival is possible in some patients. • Many level 3/4 thrombi could be safely approached without the use of bypass techniques.
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2010        PMID: 20883481      PMCID: PMC4315148          DOI: 10.1111/j.1464-410X.2010.09661.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  24 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus.

Authors:  J C Nesbitt; E R Soltero; C P Dinney; G L Walsh; D S Schrump; D A Swanson; L L Pisters; K D Willis; J B Putnam
Journal:  Ann Thorac Surg       Date:  1997-06       Impact factor: 4.330

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Venous bypass for surgical resection of renal carcinoma invading the vena cava: a new approach.

Authors:  S Attwood; D M Lang; J Goiti; J Grant
Journal:  Br J Urol       Date:  1988-05

5.  Surgery for renal cell carcinoma in the vena cava.

Authors:  V F Marshall; R G Middleton; G R Holswade; E I Goldsmith
Journal:  J Urol       Date:  1970-04       Impact factor: 7.450

6.  Rising incidence of renal cell cancer in the United States.

Authors:  W H Chow; S S Devesa; J L Warren; J F Fraumeni
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

7.  Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort.

Authors:  Igor Frank; Michael L Blute; Bradley C Leibovich; John C Cheville; Christine M Lohse; Horst Zincke
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

8.  Long-term results of resection of renal cell cancer with extension into inferior vena cava.

Authors:  J A Libertino; L Zinman; E Watkins
Journal:  J Urol       Date:  1987-01       Impact factor: 7.450

9.  A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients.

Authors:  Vincenzo Ficarra; Antonio Galfano; Francois Guillé; Luigi Schips; Jacques Tostain; Arneaud Mejean; Herve Lang; Peter Mulders; Alexandre De La Taille; Denis Chautard; Jean Luc Descotes; Luca Cindolo; Giacomo Novara; Nathalie Rioux-Leclercq; Filiberto Zattoni; Walter Artibani; Jean Jacques Patard
Journal:  J Urol       Date:  2007-06-11       Impact factor: 7.450

10.  Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience.

Authors:  Brian Shuch; Jeffrey C Larochelle; Thomas Onyia; Cristianna Vallera; Dan Margulis; Allan J Pantuck; Robert B Smith; Arie S Belldegrun
Journal:  J Urol       Date:  2008-12-24       Impact factor: 7.450

View more
  15 in total

1.  Contemporary surgical outcomes of venous tumour thrombectomy managed with intraoperative Doppler ultrasound for kidney cancer.

Authors:  Deepak K Pruthi; Hanzhang Wang; Arpan Satsangi; Miguel Cajipe; Kevan Iffrig; Georges M Haidar; Taylor Hicks; Edward Y Sako; Michael A Liss; Wasim H Chowdhury; Ronald Rodriguez; Dharam Kaushik
Journal:  Can Urol Assoc J       Date:  2018-05-14       Impact factor: 1.862

Review 2.  Management of IVC Thrombus-Surgical Strategies and Outcomes.

Authors:  Amlesh Seth
Journal:  Indian J Surg Oncol       Date:  2017-01-25

3.  Assessment of healthcare quality metrics: Length-of-stay, 30-day readmission, and 30-day mortality for radical nephrectomy with inferior vena cava thrombectomy.

Authors:  Y Joseph Hwang; Brian J Minnillo; Simon P Kim; Robert Abouassaly
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

Review 4.  Surgical treatment of renal cell carcinoma with inferior vena cava tumor thrombus.

Authors:  Shi-Min Yuan
Journal:  Surg Today       Date:  2022-01-03       Impact factor: 2.540

5.  The Prognostic Impact of a Positive Vascular Margin on pT3 Clear Cell Renal Cell Carcinoma.

Authors:  Nick W Liu; James D Wren; Emily Vertosick; Justin K Lee; Nicholas E Power; Nicole E Benfante; Simon Y Kimm; Manjit S Bains; Daniel D Sjoberg; Paul Russo; Jonathan A Coleman
Journal:  J Urol       Date:  2015-09-10       Impact factor: 7.450

6.  Tumor thrombus of inferior vena cava in patients with renal cell carcinoma - clinical and oncological outcome of 50 patients after surgery.

Authors:  Daniel Claudius Vergho; Andreas Loeser; Arkadius Kocot; Martin Spahn; Hubertus Riedmiller
Journal:  BMC Res Notes       Date:  2012-06-01

7.  Robotic Level III Inferior Vena Cava Tumor Thrombectomy: Initial Series.

Authors:  Inderbir S Gill; Charles Metcalfe; Andre Abreu; Vinay Duddalwar; Sameer Chopra; Mark Cunningham; Duraiyah Thangathurai; Osamu Ukimura; Raj Satkunasivam; Andrew Hung; Rocco Papalia; Monish Aron; Mihir Desai; Michele Gallucci
Journal:  J Urol       Date:  2015-04-06       Impact factor: 7.600

8.  Development of a surgical safety checklist for the performance of radical nephrectomy and tumor thrombectomy.

Authors:  Shivam Joshi; Michael A Gorin; Rajinikanth Ayyathurai; Gaetano Ciancio
Journal:  Patient Saf Surg       Date:  2012-12-15

9.  The minimal access technique for cavoatrial renal cancer thrombectomy - should it be used in all cases?

Authors:  Artur A Antoniewicz; Łukasz Zapała
Journal:  Cent European J Urol       Date:  2015-09-03

10.  AUTHOR'S REPLY.

Authors:  Piotr L Chlosta; Tomasz Golabek
Journal:  Cent European J Urol       Date:  2015-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.